129 related articles for article (PubMed ID: 29662635)
1. Establishment and characterization of two cabazitaxel-resistant prostate cancer cell lines.
Machioka K; Izumi K; Kadono Y; Iwamoto H; Naito R; Makino T; Kadomoto S; Natsagdorj A; Keller ET; Zhang J; Mizokami A
Oncotarget; 2018 Mar; 9(22):16185-16196. PubMed ID: 29662635
[TBL] [Abstract][Full Text] [Related]
2. CCL2 induces resistance to the antiproliferative effect of cabazitaxel in prostate cancer cells.
Natsagdorj A; Izumi K; Hiratsuka K; Machioka K; Iwamoto H; Naito R; Makino T; Kadomoto S; Shigehara K; Kadono Y; Lin WJ; Maolake A; Mizokami A
Cancer Sci; 2019 Jan; 110(1):279-288. PubMed ID: 30426599
[TBL] [Abstract][Full Text] [Related]
3. The CCL2-CCR2 Axis Contributes to Migration of Cabazitaxel-resistant Prostate Cancer Cells.
Natsagdorj A; Izumi K; Hiratsuka K; Naito R; Kadomoto S; Iwamoto H; Yaegashi H; Shigehara K; Nakata H; Mizokami A
Anticancer Res; 2023 Jun; 43(6):2561-2569. PubMed ID: 37247914
[TBL] [Abstract][Full Text] [Related]
4. The establishment of two paclitaxel-resistant prostate cancer cell lines and the mechanisms of paclitaxel resistance with two cell lines.
Takeda M; Mizokami A; Mamiya K; Li YQ; Zhang J; Keller ET; Namiki M
Prostate; 2007 Jun; 67(9):955-67. PubMed ID: 17440963
[TBL] [Abstract][Full Text] [Related]
5. Skp2 is associated with paclitaxel resistance in prostate cancer cells.
Yang Y; Lu Y; Wang L; Mizokami A; Keller ET; Zhang J; Fu J
Oncol Rep; 2016 Jul; 36(1):559-66. PubMed ID: 27175797
[TBL] [Abstract][Full Text] [Related]
6. CTEN/tensin 4 expression induces sensitivity to paclitaxel in prostate cancer.
Li Y; Mizokami A; Izumi K; Narimoto K; Shima T; Zhang J; Dai J; Keller ET; Namiki M
Prostate; 2010 Jan; 70(1):48-60. PubMed ID: 19725034
[TBL] [Abstract][Full Text] [Related]
7. A new flavonoid derivative exerts antitumor effects against androgen-sensitive to cabazitaxel-resistant prostate cancer cells.
Naito R; Kano H; Shimada T; Makino T; Kadomoto S; Iwamoto H; Yaegashi H; Izumi K; Kadono Y; Nakata H; Saito Y; Goto M; Nakagawa-Goto K; Mizokami A
Prostate; 2021 Apr; 81(5):295-306. PubMed ID: 33493355
[TBL] [Abstract][Full Text] [Related]
8. Down-regulation of E-cadherin enhances prostate cancer chemoresistance via Notch signaling.
Wang W; Wang L; Mizokami A; Shi J; Zou C; Dai J; Keller ET; Lu Y; Zhang J
Chin J Cancer; 2017 Mar; 36(1):35. PubMed ID: 28356132
[TBL] [Abstract][Full Text] [Related]
9. Serum exosomal P-glycoprotein is a potential marker to diagnose docetaxel resistance and select a taxoid for patients with prostate cancer.
Kato T; Mizutani K; Kameyama K; Kawakami K; Fujita Y; Nakane K; Kanimoto Y; Ehara H; Ito H; Seishima M; Deguchi T; Ito M
Urol Oncol; 2015 Sep; 33(9):385.e15-20. PubMed ID: 26027763
[TBL] [Abstract][Full Text] [Related]
10. Novel α-Trifluoromethyl Chalcone Exerts Antitumor Effects Against Prostate Cancer Cells.
Shimada T; Naito R; Toriumi R; Nakagawa R; Aoyama S; Kamijima T; Kano H; Kadomoto S; Iwamoto H; Yaegashi H; Izumi K; Kadono Y; Nakata H; Saito Y; Nakagawa-Goto K; Mizokami A
Anticancer Res; 2023 Jun; 43(6):2433-2444. PubMed ID: 37247901
[TBL] [Abstract][Full Text] [Related]
11. Docetaxel-resistant prostate cancer cells become sensitive to gemcitabine due to the upregulation of ABCB1.
Seo HK; Lee SJ; Kwon WA; Jeong KC
Prostate; 2020 May; 80(6):453-462. PubMed ID: 32134535
[TBL] [Abstract][Full Text] [Related]
12. Role of DNA Methylation in Cabazitaxel Resistance in Prostate Cancer.
Ramachandran K; Speer C; Nathanson L; Claros M; Singal R
Anticancer Res; 2016 Jan; 36(1):161-8. PubMed ID: 26722040
[TBL] [Abstract][Full Text] [Related]
13. Eggmanone Effectively Overcomes Prostate Cancer Cell Chemoresistance.
Xie C; Lin PJ; Hao J
Biomedicines; 2021 May; 9(5):. PubMed ID: 34066000
[TBL] [Abstract][Full Text] [Related]
14. Downregulation of cytokeratin 18 is associated with paclitaxel‑resistance and tumor aggressiveness in prostate cancer.
Yin B; Zhang M; Zeng Y; Li Y; Zhang C; Getzenberg RH; Song Y
Int J Oncol; 2016 Apr; 48(4):1730-6. PubMed ID: 26892177
[TBL] [Abstract][Full Text] [Related]
15. MRP1 not MDR1 gene expression is the predominant mechanism of acquired multidrug resistance in two prostate carcinoma cell lines.
Zalcberg J; Hu XF; Slater A; Parisot J; El-Osta S; Kantharidis P; Chou ST; Parkin JD
Prostate Cancer Prostatic Dis; 2000 Aug; 3(2):66-75. PubMed ID: 12497102
[TBL] [Abstract][Full Text] [Related]
16. Overcoming chemoresistance in prostate cancer with Chinese medicine Tripterygium wilfordii via multiple mechanisms.
Wang Z; Ravula R; Shi L; Song Y; Yeung S; Liu M; Lau B; Hao J; Wang J; Lam CW; Chow MS; Huang Y
Oncotarget; 2016 Sep; 7(38):61246-61261. PubMed ID: 27487134
[TBL] [Abstract][Full Text] [Related]
17. Exploration of the influence of GOLGA8B on prostate cancer progression and the resistance of castration-resistant prostate cancer to cabazitaxel.
Li H; Wang X; Zhai M; Xu C; Chen X
Discov Oncol; 2024 May; 15(1):152. PubMed ID: 38730195
[TBL] [Abstract][Full Text] [Related]
18. Reactive oxygen species induction by cabazitaxel through inhibiting Sestrin-3 in castration resistant prostate cancer.
Kosaka T; Hongo H; Miyazaki Y; Nishimoto K; Miyajima A; Oya M
Oncotarget; 2017 Oct; 8(50):87675-87683. PubMed ID: 29152111
[TBL] [Abstract][Full Text] [Related]
19. Differential expression of the multidrug resistance 1 (MDR1) protein in prostate cancer cells is independent from anticancer drug treatment and Y box binding protein 1 (YB-1) activity.
Saupe M; Rauschenberger L; Preuß M; Oswald S; Fussek S; Zimmermann U; Walther R; Knabbe C; Burchardt M; Stope MB
World J Urol; 2015 Oct; 33(10):1481-6. PubMed ID: 25544376
[TBL] [Abstract][Full Text] [Related]
20. Elevated circulating tissue inhibitor of metalloproteinase 1 (TIMP-1) levels are associated with neuroendocrine differentiation in castration resistant prostate cancer.
Gong Y; Chippada-Venkata UD; Galsky MD; Huang J; Oh WK
Prostate; 2015 May; 75(6):616-27. PubMed ID: 25560638
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
